Patents
274 patents filed by Insilico Medicine and related entities, of which 58 list Alex Zhavoronkov as a named inventor.
| Pub. Number | Title | Assignee | Date | Role |
|---|---|---|---|---|
| — | KINASE INHIBITORS | — | — | Inventor |
| — | METHOD AND MEDICAMENT FOR TREATING ENDOMETRIOSIS | — | — | Inventor |
| — | METHOD AND MEDICAMENT FOR TREATING ENDOMETRIOSIS | — | — | Inventor |
| — | METHOD AND MEDICAMENT FOR TREATING ENDOMETRIOSIS | — | — | Inventor |
| — | METHODS AND SYSTEMS FOR ALCHEMICAL BINDING FREE ENERGY | — | — | Inventor |
| — | Subset conditioning using variational autoencoder with a learnable tensor train induced prior | — | — | Inventor |
| — | Methods of inhibiting kinases | — | — | Inventor |
| — | Subset conditioning using variational autoencoder with a learnable tensor train induced prior | — | — | Inventor |
| — | Kinase inhibitors | — | — | Inventor |
| — | LOCAL STEPS IN LATENT SPACE AND DESCRIPTORS-BASED MOLECULES FILTERING FOR CONDITIONAL MOLECULAR GENERATION | — | — | Inventor |
| — | Analogs for the treatment of disease | — | — | Inventor |
| — | Analogs for the treatment of disease | — | — | Inventor |
| — | Mutual information adversarial autoencoder | — | — | Inventor |
| — | Analogs for the treatment of disease | — | — | Inventor |
| — | ANALOGS FOR THE TREATMENT OF DISEASE | — | — | Inventor |
| — | ANALOGS FOR THE TREATMENT OF DISEASE | — | — | Inventor |
| — | ANALOGS FOR THE TREATMENT OF DISEASE | — | — | Inventor |
| — | ANALOGS FOR THE TREATMENT OF DISEASE | — | — | Inventor |
| — | ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES | — | — | Inventor |
| — | ANALOGS FOR THE TREATMENT OF DISEASE | — | — | Inventor |
| — | METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | — | — | Inventor |
| — | TLR 9 inhibitors | — | — | Inventor |
| — | Bycyclic JAK inhibitors and uses thereof | — | — | Inventor |
| — | EDGE MESSAGE PASSING NEURAL NETWORK | — | — | Inventor |
| — | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Inventor |
| — | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | — | — | Inventor |
| — | SCAFFOLD-ORIENTED UNIVERSAL LINE SYSTEM | — | — | Inventor |
| — | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | — | — | Inventor |
| — | DETERMINISTIC DECODER VARIATIONAL AUTOENCODER | — | — | Inventor |
| — | EDGE MESSAGE PASSING NEURAL NETWORK | — | — | Inventor |
| — | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Inventor |
| — | BIOLOGICAL DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK | — | — | Inventor |
| — | TLR inhibitors | — | — | Inventor |
| — | TLR 9 inhibitors | — | — | Inventor |
| — | Methods of inhibiting kinases | — | — | Inventor |
| — | KINASE INHIBITORS | — | — | Inventor |
| — | KINASE INHIBITORS | — | — | Inventor |
| — | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | — | — | Inventor |
| — | WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET | — | — | Inventor |
| — | WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET | — | — | Inventor |
| — | TLR INHIBITORS | — | — | Inventor |
| — | KINASE INHIBITORS | — | — | Inventor |
| — | METHODS OF INHIBITING KINASES | — | — | Inventor |
| — | BICYCLIC JAK INHIBITORS AND USES THEREOF | — | — | Inventor |
| — | WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET | — | — | Inventor |
| — | Deep proteome markers of human biological aging and methods of determining a biological aging clock | — | — | Inventor |
| — | TLR inhibitors | — | — | Inventor |
| — | MUTUAL INFORMATION ADVERSARIAL AUTOENCODER | — | — | Inventor |
| — | SUBSET CONDITIONING USING VARIATIONAL AUTOENCODER WITH A LEARNABLE TENSOR TRAIN INDUCED PRIOR | — | — | Inventor |
| — | Deep transcriptomic markers of human biological aging and methods of determining a biological aging clock | — | — | Inventor |
| — | Method of treating senescence with multi-stage longevity therapeutics | — | — | Inventor |
| — | Mutual information adversarial autoencoder | — | — | Inventor |
| — | SYSTEM, METHOD AND SOFTWARE FOR ANALYSIS OF INTRACELLULAR SIGNALING PATHWAY ACTIVATION USING TRANSCRIPTOMIC DATA | — | — | Inventor |
| — | SYSTEMS, METHODS AND SOFTWARE FOR RANKING POTENTIAL GEROPROTECTIVE DRUGS | — | — | Inventor |
| — | SYSTEM, METHOD AND SOFTWARE FOR ANALYSIS OF INTRACELLULAR SIGNALING PATHWAY ACTIVATION USING TRANSCRIPTOMIC DATA | — | — | Inventor |
| — | SYSTEM, METHOD AND SOFTWARE FOR ANALYSIS OF INTRACELLULAR SIGNALING PATHWAY ACTIVATION USING TRANSCRIPTOMIC DATA | — | — | Inventor |
| — | SYSTEM, METHOD AND SOFTWARE FOR PREDICTING DRUG EFFICACY IN A PATIENT | — | — | Inventor |
| — | Systems and methods for communicating with a computer using brain activity patterns | — | — | Inventor |
| — | NOVEL COMPOUNDS AS GLUCOCORTICOID RECEPTOR MODULATORS AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 INHIBITOR COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | TEAD INHIBITOR COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | TEAD INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE TEAD INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS CYCLIC GMP-AMP SYNTHASE INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | WERNER SYNDROME RECQ HELICASE (WRN) INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | SCALABLE FRAMEWORK FOR 3D MOLECULAR DESIGN VIA LANGUAGE MODELING AND REINFORCEMENT LEARNING | — | — | Assignee |
| — | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF… | — | — | Assignee |
| — | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | SALT-INDUCIBLE KINASES (SIK) INHIBITORS | — | — | Assignee |
| — | NOVEL COMPOUNDS AS SALT-INDUCIBLE KINASES INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | WERNER SYNDROME RECQ HELICASE (WRN) INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS KRAS INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF KIF18A AND USES THEREOF | — | — | Assignee |
| — | CRBN-BINDING COMPOUNDS AND USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | TNIK INHIBITORS FOR THE TREATMENT OF PAIN | — | — | Assignee |
| — | ADVANCED RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY MODELING | — | — | Assignee |
| — | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCERS | — | — | Assignee |
| — | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR (GIPR) ANTAGONISTS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF KIF18A AND USES THEREOF | — | — | Assignee |
| — | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | — | — | Assignee |
| — | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SPIRO DERIVATIVES AS WRN INHIBITORS | — | — | Assignee |
| — | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PRMT5 INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF KIF18A AND USES THEREOF | — | — | Assignee |
| — | MPRO INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF | — | — | Assignee |
| — | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE SARS-COV-2 INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | SPIRO DERIVATIVES AS WRN INHIBITORS | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PRMT5 INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | KRAS INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | SYNTHESIS OF MACROCYCLIC COMPOUND AND MEDICAL USE OF MACROCYCLIC COMPOUND | — | — | Assignee |
| — | SUBSTITUTED THIAZOLE COMPOUNDS AS CDK2/4/6 INHIBITORS AND METHODS OF USE THEREOF | — | — | Assignee |
| — | CRYSTALLINE TNIK INHIBITOR AND USES THEREOF | — | — | Assignee |
| — | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | — | — | Assignee |
| — | PHARMACEUTICAL FORMULATIONS FOR INHALATION AND USES THEREOF | — | — | Assignee |
| — | CRYSTALLINE BETA-LACTAM DERIVATIVES AND USES THEREOF | — | — | Assignee |
| — | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | CRYTSALLINE FORMS OF ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | — | — | Assignee |
| — | BIFUNCTIONAL COMPOUNDS FOR TARGETING PKMYT1 AND METHODS OF USE | — | — | Assignee |
| — | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | — | — | Assignee |
| — | NOVEL COMPOUNDS AS PKMYT1 INHIBITORS AND USE THEREOF | — | — | Assignee |
| — | 3CL-PROTEASE INHIBITORS FOR TREATING OR PREVENTING VETERINARY CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | CBL-B INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS MODULATORS OF SODIUM CHANNELS AND USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF | — | — | Assignee |
| — | NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF | — | — | Assignee |
| — | SARS-CoV-2 inhibitors for treating coronavirus infections | — | — | Assignee |
| — | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | — | — | Assignee |
| — | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | — | — | Assignee |
| — | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | — | — | Assignee |
| — | Beta-lactam derivatives for the treatment of diseases | — | — | Assignee |
| — | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | — | — | Assignee |
| — | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | — | — | Assignee |
| — | Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof | — | — | Assignee |
| — | Lysine acetyltransferase 6A (KAT6A) inhibitors and uses thereof | — | — | Assignee |
| — | TEAD inhibitors and methods of uses thereof | — | — | Assignee |
| — | Beta-lactam derivatives for the treatment of diseases | — | — | Assignee |
| — | Structure-based deep generative model for binding site descriptors extraction and de novo molecular generation | — | — | Assignee |
| — | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | — | — | Assignee |
| — | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | — | — | Assignee |
| — | METHODS OF MANUFACTURING KINASE INHIBITORS | — | — | Assignee |
| — | SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | SPIRO DERIVATIVE AS KIF18A INHIBITOR | — | — | Assignee |
| — | INHIBITORS OF KIF18A AND USES THEREOF | — | — | Assignee |
| — | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | STRUCTURE-BASED DEEP GENERATIVE MODEL FOR BINDING SITE DESCRIPTORS EXTRACTION AND DE NOVO MOLECULAR GENERATION | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | HETEROAROMATIC COMPOUNDS AS PKMYT1 INHIBITORS AND USE THEREOF | — | — | Assignee |
| — | PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | HPK1 ANTAGONISTS AND USES THEREOF | — | — | Assignee |
| — | CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF | — | — | Assignee |
| — | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | — | — | Assignee |
| — | CBL-B INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | — | — | Assignee |
| — | METHODS OF MANUFACTURING KINASE INHIBITORS | — | — | Assignee |
| — | INHIBITORS OF TREX1 AND USES THEREOF | — | — | Assignee |
| — | TEAD INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | SPIRO DERIVATIVE AS KIF18A INHIBITOR | — | — | Assignee |
| — | CBL-B INHIBITORS AND METHODS OF USES THEREOF | — | — | Assignee |
| — | SPIROCYCLIC HPK1 ANTAGONISTS AND USES THEREOF | — | — | Assignee |
| — | INHIBITORS OF KIF18A AND USES THEREOF | — | — | Assignee |
| — | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | — | — | Assignee |
| — | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | — | — | Assignee |
| — | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | — | — | Assignee |
| — | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | — | — | Assignee |
| — | ANALOGS FOR THE TREATMENT OF DISEASE | — | — | Assignee |
| — | ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES | — | — | Assignee |
| — | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | — | — | Assignee |
| — | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | CDK8/19 DUAL INHIBITORS AND METHODS OF USE | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | — | — | Assignee |
| — | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | SUBSTITUTED MONOCYCLIC OR BICYCLIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | — | — | Assignee |
| — | Retrosynthesis systems and methods | — | — | Assignee |
| — | SCAFFOLD-ORIENTED UNIVERSAL LINE SYSTEM | — | — | Assignee |
| — | ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS | — | — | Assignee |
| — | DETERMINISTIC DECODER VARIATIONAL AUTOENCODER | — | — | Assignee |
| — | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | — | — | Assignee |
| — | GRAPH NORMALIZING FLOW FOR HIERARCHICAL MOLECULAR GENERATION | — | — | Assignee |
| — | RETROSYNTHESIS SYSTEMS AND METHODS | — | — | Assignee |
| — | RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY | — | — | Assignee |
| — | TLR 9 INHIBITORS | — | — | Assignee |
| — | GRAPH NORMALIZING FLOW FOR HIERARCHICAL MOLECULAR GENERATION | — | — | Assignee |
| — | METHYLATION DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A METHYLATION AGING CLOCK | — | — | Assignee |
| — | RETROSYNTHESIS SYSTEMS AND METHODS | — | — | Assignee |
| — | Kinase inhibitors | — | — | Assignee |
| — | Scaffold-oriented universal line system | — | — | Assignee |
| — | Workflow for generating compounds with biological activity against a specific biological target | — | — | Assignee |
| — | TLR INHIBITORS | — | — | Assignee |
| — | TLR INHIBITORS | — | — | Assignee |
| — | BICYCLIC JAK INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | BICYCLIC JAK INHIBITORS AND USES THEREOF | — | — | Assignee |
| — | DEEP PROTEOME MARKERS OF HUMAN BIOLOGICAL AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK | — | — | Assignee |
| — | DEEP PROTEOME MARKERS OF HUMAN BIOLOGICAL AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK | — | — | Assignee |
| — | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | — | — | Assignee |
| — | DEEP PROTEOME MARKERS OF HUMAN BIOLOGICAL AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK | — | — | Assignee |
| — | SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES | — | — | Assignee |
| — | KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT | — | — | Assignee |
| — | Kinase inhibitors | — | — | Assignee |
| — | Entangled conditional adversarial autoencoder for drug discovery | — | — | Assignee |
| — | MUTUAL INFORMATION ADVERSARIAL AUTOENCODER | — | — | Assignee |
| — | MUTUAL INFORMATION ADVERSARIAL AUTOENCODER | — | — | Assignee |
| — | SUBSET CONDITIONING USING VARIATIONAL AUTOENCODER WITH A LEARNABLE TENSOR TRAIN INDUCED PRIOR | — | — | Assignee |
| — | SUBSET CONDITIONING USING VARIATIONAL AUTOENCODER WITH A LEARNABLE TENSOR TRAIN INDUCED PRIOR | — | — | Assignee |
| — | KINASE INHIBITORS | — | — | Assignee |
| — | Subset conditioning using variational autoencoder with a learnable tensor train induced prior | — | — | Assignee |
| — | Withaferin compositions for prevention of aging | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |
| — | — | — | — | Assignee |